Q-omics provides the consensus-scored NDUFA4 profile across patient tissues and cancer cell-line models. NDUFA4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, NDUFA4 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, NDUFA4 protein abundance shows 23,118 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, KIRC, and GBM as cancer lineages where NDUFA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA4 survival associations across molecular data types. NDUFA4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA4 RNA expression–survival associations across cancer types. High NDUFA4 expression shows unfavorable associations in SCLC, UVM, HNSC, BLCA and LUAD, but favorable associations in THCA. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for NDUFA4 RNA expression.
This table summarizes NDUFA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA4 shows lower tumor expression in KIRC and HNSC and higher tumor expression in LIHC, COAD, BRCA and CHOL. The KIRC box plot shows higher NDUFA4 RNA expression in normal versus tumor tissue (log2 FC = −1.021, t-test p < 0.001).
This table shows molecular features associated with NDUFA4 in patient tissues and cancer cell lines. In patient samples, NDUFA4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
